Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review

BACKGROUND: The emergence of immune checkpoint inhibitors (ICIs) has brought about a paradigm shift in cancer treatment as the use of these drugs has become more frequent and for a longer duration. As a result of T-cell-mediated inflammation at the programmed cell death-1, programmed death-ligand-1,...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cardiooncology
Glavni autori: Kazama, Shingo, Morimoto, Ryota, Kimura, Yuki, Shibata, Naoki, Ozaki, Reina, Araki, Takashi, Mizutani, Takashi, Oishi, Hideo, Arao, Yoshihito, Kuwayama, Tasuku, Hiraiwa, Hiroaki, Kondo, Toru, Furusawa, Kenji, Shimokata, Tomoya, Okumura, Takahiro, Bando, Yasuko K., Ando, Yuichi, Murohara, Toyoaki
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8259377/
https://ncbi.nlm.nih.gov/pubmed/34229760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40959-021-00112-z
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items